Publications

Amrendra Kumar, K. Weller, A. Vilgelm

Engineering Technologies and Clinical Translation, 2022

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

No-Joon Song, Carter Allen, A. Vilgelm, B. Riesenberg, K. Weller, Kelsi Reynolds, K. Chakravarthy, Amrendra Kumar, A. Khatiwada, Zequn Sun, Anjun Ma, Yuzhou Chang, Mohamed Yusuf, Anqi Li, C. Zeng, J. Evans, D. Bucci, M. Gunasena, Menglin Xu, N. P. Liyanage, C. Bolyard, M. Velegraki, Shan-Lu Liu, Qin Ma, M. Devenport, Yang Liu, P. Zheng, C. Malvestutto, Dongjun Chung, Zihai Li

Journal of Hematology & Oncology, 2022

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer

Amrendra Kumar, Reese Watkins, A. Vilgelm

Frontiers in Immunology, 2021

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

B. William, J. Reneau, Amanda R. Campbell, A. Vilgelm, M. Watts, L. O’Donnell, Ying Huang, C. Chung, M. de Lima, S. Devine, S. Vasu, Dean A. Lee

Blood, 2021

Abstract 1578: Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors ‘immunologically hot' and suitable for checkpoint blockade immunotherapies

Chi Yan, Nabil Saleh, C. Nebhan, A. Vilgelm, E. Reddy, Joseph T. Roland, Douglas B. Johnson, R. Shattuck-Brandt, Sheau-Chiann Chen, G. Ayers, A. Richmond

Immunology, 2021

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Chi Yan, Nabil Saleh, Jinming Yang, C. Nebhan, A. Vilgelm, E. Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau-Chiann Chen, R. Shattuck-Brandt, G. Ayers, A. Richmond

Molecular cancer, 2021

Immunological Insights Into the Therapeutic Roles of CD24Fc Against Severe COVID-19

No-Joon Song, C. Allen, A. Vilgelm, B. Riesenberg, K. Weller, K. Reynolds, K. Chakravarthy, A. Kumar, A. Khatiwada, Z. Sun, A. Ma, Y. Chang, Mohammad Yusuf, A. Li, C. Zeng, J. Evans, D. Bucci, M. Gunasena, M. Xu, N. P. Liyanage, C. Bolyard, M. Velegraki, S.-L. Liu, Q. Ma, M. Devenport, Y. Liu, P. Zheng, C. Malvestutto, D. Chung, Z. Li

medRxiv, 2021

TREATMENT WITH SOLUBLE CD24 ATTENUATES COVID-19-ASSOCIATED SYSTEMIC IMMUNOPATHOLOGY

medRxiv, 2021

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.

R. Uzhachenko, V. Bharti, Z. Ouyang, Ashlyn Blevins, S. Mont, Nabil Saleh, Hunter Lawrence, Chengli Shen, Sheau-Chiann Chen, G. Ayers, D. DeNardo, C. Arteaga, A. Richmond, A. Vilgelm

Cell reports, 2021

Abstract 1054: Patient derived organoids demonstrate synergistic antitumor effect of senogenic and senolytic drug combination of Aurora kinase inhibitor and BCL2/xL inhibitor

V. Bharti, V. Weiss, Chengwu Shen, Sheau-Chiann Chen, Ashlyn Blevins, R. Shattuck-Brandt, A. Richmond, A. Vilgelm

Experimental and Molecular Therapeutics, 2021

Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids

A. Vilgelm, Kensey Bergdorf, Melissa M. Wolf, V. Bharti, R. Shattuck-Brandt, Ashlyn Blevins, Caroline Y. Jones, Courtney J. Phifer, Mason A. Lee, C. Lowe, Rachel A Hongo, K. Boyd, J. Netterville, S. Rohde, K. Idrees, Joshua A. Bauer, D. Westover, Bradley I. Reinfeld, N. Baregamian, A. Richmond, W. Rathmell, Ethan Lee, O. McDonald, V. Weiss

iScience, 2020

Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy

C. B. Williams, C. Nebhan, Jinming Yang, L. Starnes, Chi Yan, A. Vilgelm, Sheau-Chiann Chen, G. Dan Ayers, V. Abramson, I. Mayer, A. Richmond

Breast Cancer Research and Treatment, 2020

Obtaining patient-derived cancer organoid cultures via fine-needle aspiration

Courtney J. Phifer, Kensey Bergdorf, M. Bechard, A. Vilgelm, N. Baregamian, O. McDonald, Ethan Lee, V. Weiss

STAR protocols, 2020

Fine-Needle Aspiration Use in Organoid Research

Courtney J. Phifer, Kensey N Bergdorf, O. McDonald, A. Vilgelm, V. Weiss

Journal of the American Society of Cytopathology, 2020

Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity

Jinming Yang, Chi Yan, A. Vilgelm, Sheau-Chiann Chen, G. Ayers, Christopher A. Johnson, A. Richmond

Cancer Immunology Research, 2020

High-throughput drug screening of fine-needle aspiration-derived cancer organoids

Kensey Bergdorf, Courtney J. Phifer, V. Bharti, D. Westover, Joshua A. Bauer, A. Vilgelm, Ethan Lee, V. Weiss

STAR protocols, 2020

Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine

K. Shoghi, C. Badea, S. Blocker, T. Chenevert, R. Laforest, M. Lewis, G. Luker, H. Manning, D. Marcus, Y. Mowery, S. Pickup, A. Richmond, B. Ross, A. Vilgelm, T. Yankeelov, R. Zhou

Tomography, 2020

Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

R. Shattuck-Brandt, Sheau-Chiann Chen, Emily Murray, Christopher A. Johnson, H. Crandall, Jamye O'neal, Rami N. Al-Rohil, C. Nebhan, V. Bharti, K. Dahlman, G. Ayers, Chi Yan, M. Kelley, Rondi M. Kauffmann, M. Hooks, A. Grau, Douglas B. Johnson, A. Vilgelm, A. Richmond

Clinical Cancer Research, 2020

Abstract B20: Patient-derived organoids demonstrate synergistic effect of co-targeting Aurora kinase and prosurvival BCL2 family proteins

V. Bharti, Ashlyn Blevins, V. Weiss, Sheau-Chiann Chen, R. Uzhachenko, A. Richmond, A. Vilgelm

2020

Correction to "Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies".

Yu-Chuan Ou, Xiaona Wen, Christopher A. Johnson, Daniel Shae, O. Ayala, J. Webb, Eugene C. Lin, Rossane C. Delapp, K. Boyd, A. Richmond, A. Mahadevan-Jansen, M. Rafat, John T. Wilson, J. Balko, M. Tantawy, A. Vilgelm, R. Bardhan

ACS nano, 2020

Abstract 2552: Senescence induced by CDK4/6 inhibition facilitates anti-tumor T cell responses

Ashlyn Blevins, S. Mont, Hunter Lawrence, Nabil Saleh, Sheau-Chiann Chen, A. Richmond, A. Vilgelm

2019

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

A. Vilgelm, A. Richmond

Front. Immunol., 2019

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

A. Vilgelm, Nabil Saleh, R. Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau-Chiann Chen, C. Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al-Rohil, Ensar Halilovic, Rondi M. Kauffmann, M. Kelley, G. Ayers, A. Richmond

Science Translational Medicine, 2019

Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.

ACS nano, 2019

Abstract 4948: MDM2 antagonism overcomes resistance to CDK4/6 inhibition in melanoma

A. Vilgelm, Nabil Saleh, Kelsie Riemenschneider, Lauren Slesur, Sheau-Chiann Chen, G. Ayers, Rondi M Kauffman, M. Kelley, Douglas B. Johnson, A. Richmond

Experimental and Molecular Therapeutics, 2018

Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms

Jinming Yang, Amrendra Kumar, A. Vilgelm, Sheau-Chiann Chen, G. Ayers, S. Novitskiy, S. Joyce, A. Richmond

Cancer Immunology Research, 2018

Abstract B166: Investigating the effect of CDK4/6 and MDM2 inhibition on melanoma

Lauren Slesur, A. Vilgelm, Rami N. Al-Rohil, A. Richmond

2018

Abstract 607: Inhibition of CDK4/6 and Pi3Kγ modulates mammary tumor immune microenvironment to enhance response to immunotherapy

S. Mont, Kevin Black, Sheau-Chiann Chen, G. Ayers, A. Richmond, A. Vilgelm

Clinical Research (Excluding Clinical Trials), 2018

Abstract 513: The link between polyploidy and replication stress in melanoma

A. Vilgelm, C. Johnson, Kiran Malikayil, D. Raman, D. Flaherty, B. Higgins, A. Richmond

2017

MDM2 Antagonists Counteract Drug-Induced DNA Damage

A. Vilgelm, Priscilla Escalante Cobb, Kiran Malikayil, D. Flaherty, C. Andrew Johnson, D. Raman, Nabil Saleh, B. Higgins, Brandon A Vara, J. N. Johnston, Douglas B. Johnson, M. Kelley, Sheau-Chiann Chen, G. Ayers, A. Richmond

EBioMedicine, 2017

Using avatars to win the fight over BRAF inhibitor resistance

A. Vilgelm, A. Richmond

Pigment cell & melanoma research, 2016

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

A. Vilgelm, C. Johnson, Nripesh Prasad, Jinming Yang, Sheau-Chiann Chen, G. Ayers, Jeff S. Pawlikowski, D. Raman, J. Sosman, M. Kelley, J. Ecsedy, Y. Shyr, S. Levy, A. Richmond

Journal of the National Cancer Institute, 2016

Abstract 5126: The link between therapy-induced senescence and anti-tumor immune microenvironment in melanoma

A. Vilgelm, C. Johnson, Nripesh Prasad, Jinming Yang, Sheau-Chiann Chen, G. Ayers, J. Sosman, J. Ecsedy, Shyr Yu, S. Levy, A. Richmond

2016

Combinatorial approach to cancer immunotherapy: strength in numbers

A. Vilgelm, Douglas B. Johnson, A. Richmond

Journal of leukocyte biology, 2016

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Douglas B. Johnson, M. V. Estrada, R. Salgado, V. Sanchez, Deon B. Doxie, S. Opalenik, A. Vilgelm, Emily Feld, Adam S Johnson, A. Greenplate, M. Sanders, C. Lovly, Dennie T. Frederick, M. Kelley, A. Richmond, J. Irish, Y. Shyr, R. Sullivan, I. Puzanov, J. Sosman, J. Balko

Nature communications, 2016

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

J. Sai, P. Owens, S. Novitskiy, Oriana E. Hawkins, A. Vilgelm, Jinming Yang, T. Sobolik, Nicole A. Lavender, Andrew C. Johnson, Colt M. McClain, G. Ayers, M. Kelley, M. Sanders, I. Mayer, H. Moses, M. Boothby, A. Richmond

Clinical Cancer Research, 2016

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses

A. Vilgelm, A. Richmond

Oncoimmunology, 2015

Abstract B12: Synergistic anticancer activity of Aurora A kinase and MDM2 antagonists in melanoma

A. Vilgelm, Jeff S. Pawlikowski, Yan Liu, E. H. Oriana, A. Tyler, K. Weller, L. Horton, Colt M. McClain, G. Ayers, D. Turner, David C. Essaka, C. Stewart, J. Sosman, M. Kelley, J. Ecsedy, J. Johnston, A. Richmond

2015

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

A. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, K. Weller, L. Horton, Colt M. McClain, G. Ayers, D. Turner, David C. Essaka, C. Stewart, J. Sosman, M. Kelley, J. Ecsedy, J. Johnston, A. Richmond

Cancer research, 2015

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

Yan Liu, Oriana E. Hawkins, A. Vilgelm, Jeff S. Pawlikowski, J. Ecsedy, J. Sosman, M. Kelley, A. Richmond

Clinical Cancer Research, 2015

Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment.

K. Hockemeyer, C. Janetopoulos, A. Terekhov, W. Hofmeister, A. Vilgelm, L. Costa, J. Wikswo, A. Richmond

Biomicrofluidics, 2014

Preparation of (‐)‐Nutlin‐3 Using Enantioselective Organocatalysis at Decagram Scale.

Tyler A. Davis, A. Vilgelm, A. Richmond, J. N. Johnston

2014

Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale.

Tyler A. Davis, A. Vilgelm, A. Richmond, J. N. Johnston

The Journal of organic chemistry, 2013

Abstract 5602: Molecular mechanism underlying acquired resistance to Aurora A kinase inhibitor, Alisertib, in melanoma

A. Vilgelm, Yan Liu, S. Levy, A. Richmond

2012

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence

Yan Liu, Oriana E. Hawkins, Yingjun Su, A. Vilgelm, T. Sobolik, Y. Thu, S. Kantrow, R. Splittgerber, Sarah P. Short, K. Amiri, J. Ecsedy, J. Sosman, M. Kelley, A. Richmond

EMBO molecular medicine, 2012

Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors

Yingjun Su, A. Vilgelm, M. Kelley, Oriana E. Hawkins, Yan Liu, K. Boyd, S. Kantrow, R. Splittgerber, Sarah P. Short, T. Sobolik, Snjezana Zaja-Milatovic, K. Dahlman, K. Amiri, A. Jiang, P. Lu, Y. Shyr, D. Stuart, S. Levy, J. Sosman, A. Richmond

2012

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Clinical Cancer Research, 2012

Coordinated interaction of multifunctional members of the p53 family determines many key processes in multicellular organisms

A. Vilgelm, A. Zaika, V. Prassolov

Molecular Biology, 2011

Interactions of the p53 Protein Family in Cellular Stress Response in Gastrointestinal Tumors

A. Vilgelm, M. Washington, Jinxiong Wei, Heidi Chen, V. Prassolov, A. Zaika

Molecular Cancer Therapeutics, 2010

W1754 Role of p73 and Mechanisms of Its Regulation in Gastrointestinal Tumors

A. Vilgelm, Seung‐Mo Hong, Jinxiong Wei, W. El-Rifai, A. Zaika

2010